Возможности применения магнитно-резонансной томографии и позитронно-эмиссионной томографии с 18F-фтордезоксиглюкозой для диагностики рака молочной железы (обзор литературы и собственные клинические наблюдения)
Аннотация
Об авторах
П. Б. Гележе
ГБУЗ «Научно-практический центр медицинской радиологии Департамента здравоохранения города Москвы»
Россия
Россия
С. П. Морозов
ГБУЗ «Научно-практический центр медицинской радиологии Департамента здравоохранения города Москвы»
Россия
Россия
Список литературы
1. Appenzeller P., Mader C., Huellner M. et al. PET/CT versus body coil PET/MRI: How low can you go? // Insights Imaging. 2013. V. 4. № 4. P. 481-490.
2. Baba S., Isoda T., Maruoka Y. et al. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging // J. Nucl. Med. 2014. V. 55. № 5. P. 736-742.
3. Bellevre D., Blanc Fournier C., Switsers O. et al. Staging the axilla in breast cancer patients with 18F-FDG/PET: How small are the metastases that we can detect with new generation clinical PET systems? // Eur. J. Nucl. Med. Mol. Imag. 2014. V. 41. № 6. P. 1103-1112.
4. Chandarana H., Heacock L., Rakheja R. et al. Pulmonary nodules in patients with primary malignancy: Comparison of hybrid PET/MR and PET/CT imaging // Radiol. 2013. V. 268. № 3. P. 874-881.
5. Dregely I., Lanz T., Metz S. et al. A 16-channel MR coil for simultaneous PET/MR imaging in breast cancer // Eur. Radiol. 2015. № 25. P. 1154-1161.
6. Duch J., Fuster D., Munoz M. et al. PET/CT with [18F]-fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer // Q. J. Nucl. Med. Mol. Imag. 2012. V. 56. № 3. P. 291-298.
7. Garami Z., Hascsi Z., Varga J. et al. The value of 18F-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan // Eur. J. Surg. Oncol. 2012. V. 38. № 1. P. 31-37.
8. Gradishar W., Anderson B., Blair S. et al. Breast cancer version 3.2014 // J. Natl. Compr. Canc. Netw. 2014. V. 12. № 4. P. 542-590.
9. Groheux D., Espie M., Giacchetti S. et al. Performance of FDG PET/CT in the clinical management of breast cancer // Radiol. 2013. V. 266. № 2. P. 388-405.
10. He N., Xie C., Wei W. et al. A new, preoperative, MRI-based scoring system for diagnosing malignant axillary lymph nodes in women evaluated for breast cancer // Eur. J. Radiol. 2012. V. 81. № 10. P. 2602-2612.
11. Huellner M., Appenzeller P., Kuhn F. et al. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: Preliminary observations // Radiol. 2014. V. 273. № 3. P. 859-869.
12. Jambor I., Kuisma A., Ramadan S. et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1,5 T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial // Acta Oncol. 2015. Early Online. P. 1-9.
13. Knuttel F., Menezes G., van den Bosch M. et al. Current clinical indications for magnetic resonance imaging of the breast // J. Surg. Oncol. 2014. V. 110. № 1. P. 26-31.
14. Mainiero M., Lourenco A., Mahoney M. et al. ACR appropriateness criteria breast cancer screening // J. Am. Coll. Radiol. 2013. V. 10. № 1. P. 11-14.
15. Marinovich M., Houssami N., Macaskill P. et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy // J. Natl. Cancer. Inst. 2013. V. 105. № 5. P. 321-333.
16. Menezes G., Knuttel F., Stehouwer B. et al. Magnetic resonance imaging in breast cancer: A literature review and future perspectives // World J. Clin. Oncol. 2014. V. 5. № 2. P. 61-70.
17. Moy L., Noz M., Maguire G. Jr. et al. Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer // Breast J. 2010. V. 16. № 4. P. 369-376.
18. Pace L., Nicolai E., Luongo A. et al. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: Lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues // Eur. J. Radiol. 2014. V. 83. № 2. P. 289-296.
19. Reiner C., Stolzmann P., Husmann L. et al. Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection // Eur. J. Nucl. Med. Mol. Imag. 2014. V. 41. № 4. P. 649- 658.
20. Stolzmann P., Veit-Haibach P., Chuck N. et al. Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: Comparison of low-dose CT and Dixon-based MR imaging // Invest. Radiol. 2013. V. 48. № 5. P. 241-246.
21. Taneja S., Jena A., Goel R. et al. Simultaneous whole-body 18F-FDG PET-MRI in primary staging of breast cancer: A pilot study // Eur. J. Radiol. 2014. V. 83. P. 2231-2239.
Рецензия
Для цитирования:
Гележе П.Б., Морозов С.П. Возможности применения магнитно-резонансной томографии и позитронно-эмиссионной томографии с 18F-фтордезоксиглюкозой для диагностики рака молочной железы (обзор литературы и собственные клинические наблюдения). Радиология – практика. 2018;(6):22-34.
For citation:
Gelezhe P.B., Morozov S.P. Magnetic Resonance Imaging and Positron-Emission Tomography with 18F-Fluorodeoxyglucose Application for Breast Cancer Diagnosis (Literature Review with Case Reports). Radiology - Practice. 2018;(6):22-34. (In Russ.)
Просмотров: 185
Послать статью по эл. почте 